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Abstract: Mammalian DNA topoisomerases II are targets of anticancer anthracyclines that act by
stabilizing enzyme-DNA complexes wherein DNA strands are cut and covalently linked to the
protein. This molecular mechanism is the molecular basis of anthracycline anticancer activity as
well as the toxic effects such as cardiomyopathy and induction of secondary cancers. Even though
anthracyclines have been used in the clinic for more than 50 years for solid and blood cancers,
the search of breakthrough analogs has substantially failed. The recent developments of personalized
medicine, availability of individual genomic information, and immune therapy are expected to
change significantly human cancer therapy. Here, we discuss the knowledge of anthracyclines as
Topoisomerase II poisons, their molecular and cellular effects and toxicity along with current efforts
to improve the therapeutic index. Then, we discuss the contribution of the immune system in
the anticancer activity of anthracyclines, and the need to increase our knowledge of molecular
mechanisms connecting the drug targets to the immune stimulatory pathways in cancer cells.
We propose that the complete definition of the molecular interaction of anthracyclines with the
immune system may open up more effective and safer ways to treat patients with these drugs.
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1. Introduction
The clinical use of DNA topoisomerase inhibitors is vast in oncology as they are approved for
first-line chemotherapy for several solid and hematological malignancies. Among them, the main
drug classes are anthracyclines, epipodophyllotoxins, and camptothecins: the parent compounds
were discovered between 1960 and 1970 of the last century [1], and since then the research for better
analogs or new agents has been very intense. Nevertheless, we must admit that the parent drugs
or initially-developed analogs are still used in medical oncology. In more recent years, several
biologicals, mainly antibodies, have been developed with effective therapeutic activity, providing a
striking turn-around for cancer patient treatments [2]. Moreover, the recent combined development
of personalized medicine with more accessible individual genomic data and of immune checkpoint
inhibitors further promises to change significantly the therapy of human cancers [3,4]. In this new
context, one important question is whether anthracyclines, and other topoisomerase II poisons,
will continue to be an important asset for oncologists. Here, we present a historical view of the
molecular mechanism of anthracyclines as DNA topoisomerase II poisons, and discuss diverse findings
that need to be understood at molecular and cellular levels in a consistent framework for further
developments of anthracycline drugs in modern medical oncology.
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2. Human Top2α and Top2β are the Cellular Targets of Anthracyclines
Anthracyclines (Figure 1) are highly effective poisons of Top2 in eukaryotic cells, therefore the
biological effects of the drugs are affected by enzyme functions and activities [5]. Human DNA
topoisomerases are classified into two classes based on structure and mechanisms. Monomeric type I
enzymes (Top1) catalyze the formation of DNA single-strand breaks during the catalytic cycle, whereas
dimeric type II enzymes (Top2) introduce double-strand breaks (DSBs) in the DNA template [5–9].
Catalytic activity of Top2 is mediated through a unidirectional strand-passage mechanism by which one
DNA segment is driven through a DNA cut resulting in DNA relaxation, negative DNA supercoiling,
knotting/unknotting, and catenation/decatenation activities depending on the specific enzyme.
Top2 poisons, including anthracyclines, block the catalytic enzyme reaction stabilizing an intermediate
wherein a DNA strand is cut and covalently linked to the enzyme. As the DNA is broken, this reaction
intermediate is called a DNA-Top2 cleavage complex (Top2cc), which may eventually lead to cell
apoptosis when DNA cuts become irreversible at genomic regions of active DNA synthesis. Thus,
topoisomerase II-targeting anticancer anthracyclines increase Top2-mediated irreversible DNA damage
preferentially in proliferating cancer cells as compared to post-mitotic normal cells. Further discussions
of enzyme structures and catalytic mechanisms, and mechanisms of topoisomerase poisons can be
found in several recent reviews [5,10–14].
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Two isoforms of Top2 are present in mam als, Top2α and Top2β, the genes of which are localiz d
at chromosomes 17 and 3, respectively [10,15]. First evidence of the xistence of a second human Top2
(Top2β) were published in 1987, when distinct isoforms of Top2 were isolated [16], and in 1990 when
partial cloning of Top2β ge e from HeLa cells was reported [17]. A few years later, the complete coding
region was cloned and the recombinant Top2β was purified [18–20]. Human Top2α and Top2β show
almost 70% homology in their a ino acid sequences, mainly at the N-terminal and central catalytic
domains, whereas the major sequence divergence involves the C-terminal domain [10,15].
The functions of the two enzymes are different in cells, and here we only summarize the
information relevant to the biological effects of anthracyclines. First evidence suggesting that the
two isoforms have different functions in mammalian cells came from gene expression studies in
normal murine tissues during development [21], where Top2β was found expressed almost in all
tissues whereas Top2α gene expression was limited to tissues with a high fraction of cell proliferation.
Top2α is indeed involved in the replication process with a crucial role in the separation of DNA helices
and in chromosome compaction and segregation during mitotic divisions [5,10,22]. Consistently,
Top2α gene is highly expressed in S and G2 cell cycle phases, and is essential in eukaryotes, including
mammals as the lack of Top2α in mice leads to a very early arrest of cell division during embryonic
development [23]. As Top2α has an essential role for the disentanglement of daughter DNA helices,
other reports showed that it can interact with cohesins and SMC proteins to maintain chromatid
and chromosome structures [5,10]. In particular, Christensen et al. [24] demonstrated that, while the
interphase is characterized by the accumulation of both Top2α and Top2β in the nuclear compartment,
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particularly in nucleoli, at mitosis only Top2α becomes tightly associated with chromosomes. A recent
report then showed that Top2α causes the axial shortening of chromosomes and, along with condensin
and the chromokinesin KIF4, can shape chromosome morphology at mitosis [25]. The specific mitotic
role of Top2α vs. Top2β is likely determined by the highly divergent C-terminal domain as it
has been demonstrated that substituting this domain of the β isoform with that of the α isoform
produces an enzyme chimera that behaves as Top2α [26]. Interestingly, when the α isoform is forced
outside the nucleus by localization signal mutations, the β isoform cannot be recruited to condensing
chromatin, thus suggesting that Top2β cannot rescue a loss of Top2α for chromosome condensation
at mitosis [22,27]. Thus, Top2α is considered a marker of cell proliferation, and expression studies
in normal human tissues and cancers have shown that it is often overexpressed in aggressive or
rapidly proliferating tumors, while it is undetectable in differentiated and quiescent cells [28,29].
Top2β is instead ubiquitously expressed at significant levels in normal tissues and cancers, however it
is generally more expressed in proliferating cells and tumors [28,30].
The roles of Top2 isoforms in transcription and transcription regulation is an active research area.
Either Top2 and Top1 can relax torsional stress of DNA template during transcription to allow RNA
polymerase elongation [5,31], however they are recruited at different regions of active genes such as
promoters or along the entire gene, respectively [32]. While Top1 is generally needed at all transcribed
genes, Top2 has been proposed to be required especially at highly active genes to resolve the high
rate of torsional stress generated by RNA polymerases [32]. In addition to this basic topology-related
function, Top2 isoforms have been proposed to have specific functions in transcription regulation at
different developmental stages.
A burst of Top2β gene expression was reported in mouse brains immediately after birth suggesting
a critical role of the β isoform in brain development [21], which was further supported by a later
paper showing an alteration of neuronal development in brain-specific Top2β depleted mice [33].
In addition, Top2β knockout mice exhibited perinatal death due to severe neuronal defects affecting
their respiratory tracts [23,34]. Successive microarray analyses of Top2β-knockout mouse brains
demonstrated recruitment of this enzyme at gene promoters at late stages of neuron differentiation [35].
Top2β was also found to bind H3K4-dimethylated promoters of actively transcribed genes in mouse
neuronal cells [36], and in particular it was associated with the expression of long genes [37]. Another
report showed that Top2α is preferentially recruited at promoters of transcribed genes in murine
embryonic cells [38]. Interestingly, many housekeeping genes are targets of both Top2α and Top2β in
embryonic and terminal differentiated cells, respectively, while unique gene targets have functions
in pluripotency and neurogenesis pathways, respectively. Top2α activity is also critical for high
transcription rates of major ribosomal RNA genes (rDNA) in growing cells as it interacts with the
transcription factor RRN3, which recruits RNA polymerase I to rDNA promoter along with Top2α [39].
In growing cells, the activation of rDNA transcription is accompanied by transient DNA cleavage at
the promoter, which is dependent on Top2α, suggesting that this enzyme can modulate DNA topology
at the rDNA promoter which is needed for pre-initiation complex formation [39].
In terminal differentiated cells, transient DNA cleavage mediated by Top2β has been proved to
occur at certain promoter regions and to be required for transcriptional gene activation. Interestingly,
Chd7 (chromodomain helicase DNA-binding protein 7) is needed along with Top2β for the expression
of long neuronal genes in granule neurons of mouse cerebellum revealing a Top2β-dependent pathway
of chromatin remodeling for cell-specific gene expression [40]. Madabhushi et al. demonstrated that
etoposide, a poison of Top2, could lead to the up-regulation of the early-response genes Fos and Npas4
in neuronal cells [41] and that Top2β is enriched by ChIP analyses at gene promoter region [41,42].
Moreover, the report showed reduced levels of double-strand breaks at the Fos promoter of neurons
with decreased Top2β levels upon NMDA (N-methyl-D-aspartate) stimulation suggesting that Top2β
is required for double-strand breakage formation for rapid gene activation [41]. Similarly, transient
double-strand breaks by Top2β were also observed at the pS2 promoter upon 17β-estradiol (E2)
stimulation and required for transcriptional activation of target genes [43]. ChIP analyses show that
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Top2β recruitment sites are enriched in gene promoters and that E2 can modulate the profiles of
Top2β-binding sites modulated in the genome [44]. Thus, Top2β activity may have a specific role in
transcription regulation of specific genes in terminal differentiated neurons, raising the question of
which are the factors driving the recruitment of the enzyme to chromatin sites.
Recently, a transcription-independent Top2β activity was shown to occur at anchor sites of
topologically-associated domains (TADs). Genomic maps of Top2β binding sites in chromatin of
interphase cells showed that this isoform was associated not only with active genes but also with
CTCF/cohesin-bound chromatin regions close to TAD boundaries [45]. By genome mapping of
Top2β-mediated double-stranded breaks, it has been shown that the β isoform can promote breakage
at chromatin-bound sites in interphase cells. Interestingly, these DNA breaks are concentrated at loop
anchors of TADs along with the presence of CTCF and Rad21, a subunit of the cohesin complex [46].
These reports suggest that Top2β can resolve DNA torsional stress of TADs acting at loop anchor
regions. Interestingly, those regions have been associated with sites of DNA translocations frequently
found in secondary cancers developed after a chemotherapy regimen containing Top2 poisons such as
anthracyclines and etoposide [45,46] (see also below).
3. Top2 Poisoning Activity of Anthracyclines
It is widely accepted that the effective anticancer activity of anthracyclines is due to the drug
cell killing activity that is specific for proliferating cancer cells. A vast amount of published
data demonstrates that the cellular target of anthracyclines, relevant for their therapeutic activity,
is Top2 [47–49]. These drugs interfere with both human Top2 isoforms [50]: the drug action on Top2α
is generally considered the molecular basis of anthracycline activity as this isoform has a main role
during replication and cell proliferation [13,51]. In contrast, Top2β has been associated with long-term
side effects of anthracyclines such as cardiotoxicity and secondary malignancies (see below), however
Top2β may contribute to cell killing activity as well [15,50,52].
The mode of action of anthracyclines (Figure 1) in interfering with either Top2 isoforms is very
similar, as shown by structural, biochemical and cellular studies [12,51,53]. The drugs are very
potent and efficient in stabilizing Top2cc [47,48,54], resulting therefore in highly lethal DNA breaks
in proliferating cancer cells [55,56]. Initial findings clearly showed that anticancer Top2 poisons of
different structural families induce DNA cleavage in a sequence-selective manner, which can be
revealed experimentally as drug-specific cleavage intensity patterns in sequencing gels [47,48,57].
To establish the mode of action of anthracyclines, early studies investigated the distribution and
nucleotide sequence environments of doxorubicin-enhanced sites in defined DNAs, such as SV40
genome with purified Top2. Distributions of DNA cleavage sites induced by Top2 in the presence of
diverse drugs resulted in distinctive patterns of enhanced cleavage. DNA cleavage usually occurred
on both DNA strands with the expected four base-pair 5’ stagger and strong sites tended to occur
within AT-rich tracts such as the major nuclear matrix-associated SV40 DNA [58]. In contrast to other
drugs, such as etoposide, doxorubicin-specific sites were found to be most concentrated at A/T runs
of in-vitro studied DNA fragments. Interestingly, cleavage intensities changed with time depending
either on the site or on the drug, suggesting that Top2 can move along the DNA from a kinetically- to a
thermodynamically-preferred site [58]. A striking finding was that among doxorubicin-stabilized sites,
none coincided with any of the Top2 II cleavage sites observed without drugs [59]. DNA cleavage
at enzyme-only sites declined over time with doxorubicin and was never stimulated by the drug.
The sequence selectivity was due to the doxorubicin requirement for an A at the 3’ terminus of at least
one of the two strand breaks produced by Top2. Conversely, none of the enzyme-only sites had an A
simultaneously at 3’ termini of the DNA cleavage. Thus, the findings showed that 3’-A requirement
for anthracycline-enhanced DNA cleavage was not compatible with Top2-only cleavage explaining
the reciprocal exclusivity of the two site sets, which was likely due to a different thermodynamic
equilibrium [59].
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Different Top2 poisons have different nucleotide requirements at positions adjacent to the strand
break, including −2, −1, +1, and +2 positions, leading to a classification of structurally-unrelated
poisons in distinct functional classes [53,60–63]. This knowledge was based on different experimental
approaches: (i) statistical analyses of hundreds of DNA cleavage sites promoted in vitro by Top2
in the presence of different agents; (ii) mutational studies of cleavage sites, and (iii) cross-linking
of photo-inducible analogs [62,64,65]. Altogether these findings led to a common molecular model
of the action of Top2 poisons: a Top2 poison binds at the interface of the enzyme/DNA complex
forming a ternary complex wherein the poison binds to its receptor at the site of DNA cleavage
impeding strand religation and interacting with both DNA bases and active site amino acid residues of
Top2 [59,64,66]. Different compounds likely interact differently with the receptor site thus explaining
the DNA site selectivity resulting in specific cleavage intensity patterns in sequencing gels [67]. Thus,
altogether these findings showed that Top2 poisons are peculiar compounds as their target is a binary
enzyme-DNA complex rather than each component alone [53]. This model was then expanded further
leading to the “interfacial inhibitor” model [68]. Recent X-ray crystal investigations added the last and
final evidence of the model as Top2 poisons were shown to be placed at the predicted site [69]. During
the following years, this knowledge led to several attempts to rationally design either hybrid poisons
with effective pharmacological activity, fusing for instance structural determinants of etoposide with
those of DNA intercalating agents or dual-enzyme poisons directed against both Top2 and Top1 [70,71].
Interestingly, these attempts are still very active in the field [72,73], and may eventually lead to a better
anticancer topoisomerase poison in the future.
Doxorubicin and other anthracycline analogs have very peculiar Top2-related effects at cellular
levels. Dose response curves of DNA damage induced by doxorubicin demonstrated a dose-dependent
level of DNA damage but up to a certain concentration only, as at higher concentrations DNA damage
levels dropped to control levels [54,74,75]. Therefore, these bi-phasic dose-response curves are due to
the direct action of anthracyclines on Top2cc as very similar curves were observed in in-vitro DNA
cleavage assays using purified enzymes [47,48]. This phenomenon is peculiar to anthracyclines and
other high-affinity DNA intercalating agents, and is due to the strong affinity of the compound for
DNA duplexes that prevents Top2 from binding to DNA. Interestingly, in living cancer cells DNA
cleavage levels are progressively reduced over time when doxorubicin is removed from the culture
medium, however when doxorubicin concentration was high, DNA cleavage levels started to increase
upon drug removal from the medium [75]. This was somewhat surprising but it can be understood
by the specific dual action of anthracyclines: strong binding to both Top2cc and DNA duplexes.
These peculiar aspects of cellular drug activity must be considered when investigating the molecular
mechanisms and pathways activated by anthracyclines or other strong DNA binders.
Few investigations have been published on the sequence specificity of Top2 poisoning by
anthracyclines in chromatin of living cells. This is due to the general belief that Top2-mediated
DNA cleavage is determined by the enzyme with little influence of the chemical used. However,
different poisons promoted DNA cleavage by Top2 at different sequences in in vitro systems and in
living cells. Using D. melanogaster Kc cells, an anthracycline analog, clerocidin and VM-26 (a VP-16
analog) were shown to have highly different cleavage sequence patterns at transcriptionally-active and
-silent chromatin [76–78]. These reports revealed that Top2 could be localized to promoter of histone
genes only with two poisons (anthracyclines and clerocidin) while VM-26 was ineffective in localizing
Top2 at these particular genomic sites. The results thus showed that a loose sequence specificity of
poisons can become a determinant of cleavage localization in chromatin as the presence of nucleosome
can markedly restrict the accessibility of DNA to Top2 [79].
4. Cardiotoxicity and Secondary Cancers Caused by Anthracyclines
The production of reactive oxygen species in heart cell mitochondria has often been proposed as a
molecular base of drug cardiac toxicity [80]. It is argued that when drugs reach a high concentration in
the blood of patients, the generation of reactive oxygen species becomes significant and constitutes the
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main cause of damage to cardiomyocytes that heavily depend on mitochondria energy metabolism.
However, other findings argue against a significant role of oxygen radicals in anthracycline clinical
effects. Both Top2α and Top2β are transported into mitochondria of mammalian cells [81], however
in cell tissues that do not express Top2α, such as terminal differentiated cardiomyocytes, only the
β isoform is present. This knowledge led to investigations of the role of Top2β in anthracycline
cardiotoxicity. In 2007, Liu et al. demonstrated γH2AX induction in H9C2 cardiomyocytes after
doxorubicin treatment in a dose-dependent manner with high levels of DNA damage observed at low
concentration of drug [82]. DNA damage by doxorubicin was likely due to the β isoform as MEF cells
depleted of Top2β exhibited reduced γH2AX levels and sensitivity to doxorubicin [82]. In a mouse
model of cardiomyocyte-specific deletion of Top2β gene, the lack of Top2β in heart cells was shown
to protect mice from doxorubicin-induced heart cell damage and development of progressive heart
failure [83]. The tissue-selective deletion of Top2β gene did not impair mice life or heart functions,
suggesting that Top2β is not required for normal homeostasis of adult hearts. Transcriptome analyses
showed down-regulation of proapoptotic genes in Top2β-depleted cardiomyocytes after doxorubicin
treatment. Doxorubicin caused major alterations of mitochondria functionality in WT hearts whereas
mithocondrial dysfunctions were much reduced in Top2β knockout cardiomyocytes [83]. These drug
effects can lead to an increase of reactive oxygen species, which is likely a consequence rather than the
cause of mitochondria dysfunction following doxorubicin poisoning of Top2β in mitochondria. Thus,
the knowledge that Top2β is the cellular target responsible for heart failures caused by anthracyclines
is a strong rational for the discovery and development of new anthracycline analogs (in general,
new Top2 poisons) more specific for Top2α than Top2β (see below).
Top2-mediated DNA cleavage has long been suspected to cause chromosome translocations that
can lead to oncogene activation and secondary cancers in patients treated with Top2 poisons for a
primary cancer [84]. Secondary cancers after a primary cancer-related therapy have become a concern
as cancer survivors have an increased risk of secondary tumors. A recent review has shown that
childhood cancer survivors have more than two-fold increased risk for acute leukemia/myelodysplasia
and solid tumors after the age of 40 [85]. Beyond radiation, a well-studied cause of secondary
cancers, alkylating agents and Top2 poisons (etoposide, doxorubicin and mitoxantrone) have the
best-established association with secondary cancers. In particular, anthracyclines are associated with
acute leukemia/myelodysplasia and solid tumors including breast cancers and sarcoma [85].
Top2β, but not Top2α, appears to play a main role in the increased cancer incidence in patient
survivors. In a mouse model of skin melanoma induced by etoposide, the skin-specific deletion of
Top2β gene has been shown to protect skin cells from cancer transformation [81]. Consistently,
it has been shown that the Top2β poison induced DNA damage and genome rearrangements,
which were dependent on proteolysis of Top2βccs [86]. Secondary acute myeloid leukemias in
patients are often characterized by balanced translocations involving the mixed lineage leukemia
(MLL) locus at chrm11q23, which most often occurs at a 8-kb breakpoint cluster region (BCR) [84].
Interestingly, the MLL BCR share distinct DNA and chromatin features with BCRs of other genes
involved in chromosomal translocations found in secondary leukemia [84]. These features include
matrix-attachment sequences, CTCF binding, DNaseH1 hypersensitivity, specific histone patterns,
and Top2 DNA cleavage sites [87–89]. As chromosome translocations can be due to non-homologous
joining of DNA ends belonging to different chromosome, it is interesting to note that Top2 DNA
cleavage sites are very close to translocation sites detected in secondary acute leukemia [84,88].
As broken DNA ends should be close to each other to be joined by DNA repair mechanisms,
the proximity of expressed MLL and partner genes has been investigated in interphase cells [90].
Cowell et al. demonstrated that the transcribed MLL gene is often in close proximity or even in the
same transcription factory to one of the translocation partner genes. In addition, etoposide-induced
DNA cleavage and genomic instability are markedly dependent on Top2β but not Top2α isoforms.
Thus, the findings suggest that an illegitimate end-joining repair event can occur as two partner genes
are transcribed in the same factory and are cleaved at their BCRs by etoposide-stabilized Top2βcc [90].
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Interestingly, BCRs of MLL and other partner genes have chromatin characteristics in common with
“loop anchors” of TADs (see above) where Top2β has been shown to be active and to modulate DNA
topology of chromatin domains [46].
Thus, therapy-related chromosomal translocations causing secondary cancers can be due to poison
interference with Top2β rather than Top2α. Several studies on the mechanisms of secondary cancers
have focused on etoposide, and not anthracyclines, however the findings are relevant for all clinically
used Top2 poisons as they are not specific for one isoform. Future studies will establish the precise
mechanisms in the case of doxorubicin and other drugs. Current knowledge also emphasizes the
importance of developing Top2α-specific poisons as anticancer drugs to avoid the cardiomyopathies
and secondary cancers caused by anthracyclines and other Top2 poisons.
5. Current Attempts to Improve the Clinical Efficacy of Anthracyclines
To overcome doxorubicin-induced cardiomyopathy in cancer patients, dexrazoxane (ICRF-187 or
Zinecard) has been approved and is currently used in combination with doxorubicin for metastatic
breast cancer patients that have been treated already with ≥300 mg/m2 of doxorubicin [91].
Dexrazoxane is a Top2 catalytic inhibitor as it is able to bind to the ATPase domains in the N-terminal
region and to block enzyme activity preventing the start of the catalytic cycle [82,92]. Liu et al. [82]
demonstrated the effects of dexrazoxane on DNA damage and Top2β stability in heart cells. Attenuated
effects on DNA damage levels by dexrazoxane were observed in H9C2 cardiomyocytes after
doxorubicin treatments suggesting the implication of Top2β in the protective effect of dexrazoxane.
In contrast, no change was shown in γH2AX signal after CPT treatment alone or in combination with
dexrazoxane. Incubation with dexrazoxane was demonstrated to induce proteasomal degradation
of Top2β but not Top2α in cardiomyocytes preventing DNA damage formation after doxorubicin
treatment [82].
Catalytic inhibitors of Top2 can therefore be used to avoid toxic effects of anthracyclines and
several attempts have been made to develop isoform-specific Top2 inhibitors ([93] and references
therein). However, Top2β-specific inhibitors could be even better compounds as they would not affect
Top2α. In contrast, to optimize the antitumor activity, current research efforts aim at the discovery of
Top2α-specific poisons, which are expected to not induce cardiomyopathies and secondary cancers,
likely due to the Top2β. Structural enzyme similarities of human Top2 isoforms make difficult the
discovery of isoform-specific small molecules acting as poisons, however screening programs can
find isoform-specific agents [94]. Interestingly, a synthetic phenanthridine alkaloid (NK314) has been
shown to act as a Top2α-specific poison in cancer cells [95]. This compound can increase Top2αccs,
but not Top2βccs, in cultured cells and gene deletion of the former, but not the latter, confers cell
resistance to NK314 suggesting that Top2α is the cellular target of this compound in vivo. NK314 has
been shown to act as a dual inhibitor of Top2α and DNA-dependent protein kinase [96], suggesting that
the cell killing activity is potentiated by targeting two enzymes. Interestingly, pixantrone, a compound
structurally-close to anthracyclines, has been shown to target more effectively Top2α than Top2β in
living cancer cells [97].
Moreover, anthracycline-based agents or complexes have been developed with the common aim
of reducing the toxic effects and improving the therapeutic index. This could be achieved by (i) the
development of molecules with new structure; (ii) drugs or prodrugs conjugated to selected antibody
or loaded on nanostructures for specific tumor targeting. Here, we summarize recent advances related
to these two general attempts.
5.1. Discovery of New Analogs
Modifications of the sugar moiety (Figure 1), a structural determinant for Top2 poisoning
and anticancer activities of anthracyclines, have been attempted to enhance target recognition.
In particular, disaccharide analogs have been developed and their cell killing and anticancer activities
were specifically dependent on reciprocal spatial orientation of sugar monomers. The results
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reveal an important role for the second (non-DNA interacting) sugar in drug activity, however the
pharmacological effects of disaccharide analogs could not be fully explained by interference with
Top2 [98]. Interestingly, parent drugs and disaccharide derivatives have been reported to remove
nucleosomes (nucleosome eviction) at open chromatin regions with consequences on the epigenetic
regulation of transcription and reduced DNA repair of double-strand breaks caused by the drugs [99].
The new mechanism is specific for anthracyclines as other Top2 poisons do not share the effect
on nucleosomes, and the drug-altered nucleosome remodeling may explain at least partially the
resistance of acute myeloid leukemia cells to anthracyclines [100]. Whether this new mode of action
of anthracyclines contributes to the biological drug activities needs to be fully established with
further studies.
The topopyrones are interesting fungal products with an anthraquinone–polyphenolic structure,
very similar to the anthracycline planar ring moiety, which act as poisons of both Top1 and Top2.
Zaleski et al. [72] performed structure–activity studies to define which orientation of the fused
1,4-pyrone ring and halogen substituents contribute to the Topoisomease poisoning activity of
Topopyrones. Therefore, they defined a pharmacophore able to stabilize both Top1cc and Top2αcc.
Other compounds that have been demonstrated to be dual Top1 and Top2 inhibitors are the
Ruithenim–anthraquinone complexes synthesized by Kou et al. [73].
Shchekotikhin et al. [101] worked on anthra[2,3-b]furan-3-carboxamides and found that some
compounds are dual Top1/Top2 inhibitors. These agents form stable intercalative complexes with
duplex DNA and attenuate Top1 and Top2 relaxation activity with a mechanism that is probably
different from poisons. Other Top2 inhibitors, structurally similar to anthracyclines, that do not
act as poisons are bisanthrapyrazole compounds containing piperazine linkers synthesized by
Zhang et. al. [102]. These derivatives strongly inhibit the decatenation activity of Top2α without
Top2cc stabilization and can also block the relaxation activity of Top1.
5.2. Specific Delivery of Anthracyclines
To improve drug solubility and stability, extend drug half-lives, increase drug concentrations
at cancer tissues, a wide research activity has focused on the optimization of drug delivery with
liposomes, functionalized nanoparticles, dendrimers or micelles [103]. Several groups have reported
many combinations of drug, loaded on different nanosystems, which were tested in vitro and in vivo.
Here, we summarize recent reports related to anthracyclines.
Ke et al. [104] incorporated into the surface of doxorubicin loaded liposomes, eight repeated
sequences of aspartate (Asp8) and folate, obtaining a dual-targeting liposomal system in which Asp8
target preferentially the resorption surface of bones and folate target the tumor cells. They nicely
demonstrated by in vivo distribution imaging and binding assay, that the system has a strong bone
targeting effect and high cytotoxicity, associated with a prolonged blood circulation time which favored
drug accumulation in the tumor. This system could potentially be used in bone metastasis of breast
cancers as normal doxorubicin uptake is poor in such metastatic sites due to bone microstructures.
A promising approach to specifically target cancer tissues is based on the conjugation between
monoclonal antibody and anticancer drugs. CD147 is localized on the surface of tumor cells but not
in normal tissue and promotes tissue invasion by cancer cells. Asakura et al. [105] took advantage of
the antigen to test the therapeutic effect of anti-CD147-labeled polymeric micelle-encapsulated with
a conjugate of doxorubicin and glutathione (GSH-DXR), which they previously demonstrated to be
more potent compared to doxorubicin alone. Micelles accumulated quickly in cancer cells, in a manner
dependent on CD147 expression, showing a specific and highest cytotoxicity in CD147-expressing
carcinoma cells. The data suggest that the drug-conjugated micelles could serve as an effective delivery
system in CD147-expressing tumors. Madhankumar et al. [106,107] focused on IL13Rα2, a cancer
associated receptor with an important role in tumor cell migration, invasion, and anti-apoptotic
activity. They looked for IL13Ra2 presence in several carcinoma tissues and tested liposomal
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IL13-conjugated doxorubicin against glioblastoma tumors and in malignant peripheral nerve sheath
tumors, demonstrating a decrease of tumor burden both in vitro and in vivo [108].
Santiago et al. [100,109] immobilized gemcitabine and doxorubicin on gold nanoparticles through
a pH-sensitive amide bond, which allows the release of drugs only at acidic pH, a characteristic of
cancer cells. In addition to this system, they also modified these nanoparticles adding the folate,
obtaining a targeted controlled-release delivery of the drug, reducing the side effects, and increasing
the efficacy. Han et al. [110] developed a new nanocarrier that delivered doxorubicin combined with
rhein to suppress progression of human ovarian cancer cells with drug resistance, while Xu et al. [111]
loaded mitoxantrone (structurally similar to antharcyclines) and verapamil in polysaccharide-based
nanoparticles to overcome multidrug resistance in breast tumor. Other two recent works have provided
interesting results. Wu et al. [112] developed a lipid-coated hollow calcium phosphate nanoparticle for
the combined application of doxorubicin and paclitaxel to human lung cancer A549 cells. Shi et al. [113]
developed photo-activated nanoliposomes that, after a light-initiated and rapid release of antitumor
drug doxorubicin, imparted cytotoxicity and reversal of drug resistance. All these recent publications
indicate that the specific targeting of anthracyclines to tumor tissues could be a winning strategy to
overcome drug toxicity and improve efficacy.
6. Interactions of Anthracyclines with the Immune System
Historically, the idea of combining immunotherapy and chemotherapy was proposed soon
after daunomycin discovery, as parent drugs daunomycin and adriamycin (Figure 1) were
observed to synergize with the immune viral response in a mice model of Moloney virus-induced
tumors [114,115]. However, these lines of investigations were abandoned during the next decades
as anthracycline-containing chemotherapies were considered to kill proliferating tumor cells,
via apoptosis or necrosis, in a manner independent from the immune system of patients. However,
this common thought has changed in recent years as, for instance, murine tumors are much more
sensitive to anthracyclines when they grow in syngenic immunocompetent than immunodeficient
animals [116].
Several studies have established that anthracyclines can have cytostatic effects and can lead
cells not only to apoptosis, but also to cell senescence or other types of death programs, including
immunogenic death [117,118]. Anthracycline-induced (and more generally, DNA damage-induced)
senescence is not due to telomere shortening and cannot be rescued by telomerase expression, which are
instead molecular characteristics of normal cell proliferation limits. Terminal proliferation and
senescence were shown to be induced by low-cytotoxic doses of doxorubicin in a number of cancer
cell lines [117]. The terminal arrest was dependent on p53 and p16INK4a tumor suppressor genes and
occurred within a few cell cycles from doxorubicin treatment. Interestingly the authors also described
the occurrence of micronuclei formation promoted by the drug, which was associated with mitotic
death [117]. Even if senescent cells cannot proliferate, they are still metabolically active, and can
therefore interact with other normal or cancer cells in patients. How this can affect the anticancer
activity of anthracyclines needs to be better understood.
The mechanistic ways a cancer cell can die upon treatment with chemotherapeutics constitute
an active research area. Cell death programs appear to be diverse and therefore the definition of the
nature of cell death under any condition has become complex. Currently, a consensus has emerged
recommending that a cell death should be defined by distinct molecular, biochemical, metabolic,
and morphological hallmarks [119–121]. Interestingly, a new cell death modality has been recognized:
the immunogenic cell death (ICD) that is characterized by dead-cell antigens released by dying cells
and able to elicit specific immune responses against cancer cells [117,118]. This pathway utilizes
signals emanating from dying cancer cells to inhibit cancer growth and was first defined in a context of
anti-cancer chemotherapy using anthracyclines [116]. A comparison of doxorubicin and mitomycin C
(a doxorubicin-unrelated agent) showed that doxorubicin-induced dying cells were immunogenic in a
variety of cancer cell types, whereas dying cells due to mitomycin C were not. Caspase activation was
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also a determinant of immune response as inhibition of caspase fully abolished the immunogenicity of
doxorubicin-induced dead cells. However, as caspase was also activated in mitomycin C treated cells,
it was proposed that specific factors were present only in doxorubicin-treated cells, which however
remained to be established [116]. Further analyses have shown that specific aspects of immunogenic
cell death are the early exposure of reticular chaperone calreticulin on the dying cell surface, the late
release of the nuclear non-histone protein HMGB1 (high mobility group B1), and the secretion
of ATP extracellularly. These factors are recognized by specific receptors of dendritic cells (DCs)
which then activate an immune response against cancer cells [118,122]. Interestingly, autophagy is
required for optimal ATP release but dispensable for the emission of other immunogenic signals [123].
This has a consequence on drug activity as autophagy is dispensable for mitoxantrone-induced cell
death—mitoxantrone shares the antraquinone planar ring moiety with anthracyclines—but required
for its immunogenicity. The findings indeed showed that autophagy can contribute to the drug
therapeutic effects by provoking an anticancer immune response [123].
However, the effects of anthracyclines, and other chemotherapeutics, on cancer cells can even be
more complex as drugs can also enhance the expression of specific interferon genes directly in treated
cancer cells that then stimulate the innate immunity of the host. In the later 1990s, doxorubicin and
other DNA damage agents were shown to activate IRFs (interferon regulatory factors) in human cancer
HeLa cells [124,125]. IRFs have protective functions in cell defense mechanisms against environmental
stresses, including viruses and bacteria. In particular, doxorubicin activates IRF1 gene expression while
increasing the phosphorylated form of IRF3, suggesting that IRF1 and IRF3 may work in a protective
pathway constituted by an immediate IRF3-dependent response and a later IRF1-dependent phase.
IRF1 can modulate specific target genes, thereby inducing cell cycle arrest, while IRF3 is phosphorylated
during viral infections and translocates in the nuclear compartment to activate the transcription of
target genes [124,125]. More recent papers have shown that IRF3 is involved in the STING pathway that
activates the transcription of type I interferons upon the occurrence of cytoplasmatic nuclei acids [126].
The IRF protective pathways lead to transcriptional activation of genes with antiproliferative, apoptotic,
antiviral, and immuno-stimulatory activities. Therefore, anthracycline-induced IFN responses and
immune system stimulation may contribute to the antitumor activity of doxorubicin [127,128].
Interestingly, it has become clear that several molecular features of immune response to viral
infections are similar to successful anticancer chemotherapies based on anthracyclines. Such ‘viral
mimicry’ has been even suggested to be a hallmark of clinically-effective chemotherapy [129].
Anthracyclines can activate the expression of type I interferons by an autocrine and paracrine circuitry,
which depends on TLR3 (Toll-like receptor 3) and TLR4 signaling and release of RNA during cell
death. A retrospective analyses of cohorts of patients with breast cancers showed that high expression
of type I Interferon gene signature predicts the response to anthracycline-based chemotherapy in
subsets of patients [129]. These findings may open up individualized therapy based on immunological
characteristics of patient tumor and the targeted delivery of type I interferon in patients with low
interferon expression.
More recently, from a screening of 2080 bioactive compounds, five agents, including four
anthracyclines, were shown to induce the IFN response in an ATM kinase-dependent manner
upon Ebola virus infection of human cells. The compounds activated the STING pathway of IFN
induction resulting in the inhibition of virus replication [130]. Interestingly, viral proteins, which can
effectively inhibit host immune-response genes, could not prevent IFN response by doxorubicin.
Overall, the report suggests that doxorubicin-mediated IFN activation may be due to two distinct,
ATM- or STING-dependent pathways. Another recent paper on hepatitis B virus (HBV) showed
that daunorubicin can trigger innate immune response in a cGAS-dependent manner preventing
HBV production in human hepatocytes [131]. Therefore, overall these results support the fact that
anthracyclines can activate the STING-cGAS pathway activating type I interferons in cancer cells.
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7. Conclusions
Sixty years since the discovery of daunorubicin [1], this class of antitumor antibiotics is still
an essential component of effective chemotherapeutic regimen of solid and hematopoietic cancers.
While the tremendous efforts of the past decades aimed at the discovery of more effective analogs have
substantially failed, major advances in cancer genetics can now provide precise genetic information
for selecting patients that will gain the most from a treatment with anthracyclines. At the same
time, the more recent developments of very effective immunotherapies of solid tumors open up the
possibility of improved combinations of immunotherapy and chemotherapy. The appreciation of the
contribution of the immunological system in the anticancer activity of anthracyclines has revealed
unexpected immunological effects induced by these drugs. Interestingly, the effects are not specific
for anthracyclines, as they have been reported to occur also for other, but not all, anticancer agents
such as cisplatin derivatives and ionizing radiation. A common feature of these agents is the ability to
damage the DNA, however the mechanistic link between DNA damage and the immune response is
not yet clear. In particular, the molecular mechanisms connecting the anthracycline targets (Top2α and
Top2β), in the nucleus/mitochondria, to the STING-cGAS pathway, in the cytoplasm, remain to be
fully established. We expect that the complete definition of structural aspects and molecular pathways
of the interaction of anthracycline with the immune system may open up new opportunities of clinical
utility of these Top2 poisons.
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